Cidara Therapeutics, Inc.
CDTX$6.92B
Mid CapNASDAQBiotechnology🇺🇸North America38 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
CDTX News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Rezafungin for Injection
Candidemia
CD101 Vaginal Gel (3%)
Candidiasis, Vulvovaginal
CD101
Candidemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rezafungin for Injection | Phase 3 | Candidemia | - | - |
CD101 Vaginal Gel (3%) | Phase 2 | Candidiasis, Vulvovaginal | - | - |
CD101 | Phase 2 | Candidemia | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply